Fresenius Medical Care AG (FMS)
20.75
+0.64
(+3.18%)
USD |
NYSE |
May 08, 13:21
Fresenius Medical Care Research and Development Expense (Quarterly): 51.92M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 51.92M |
| December 31, 2023 | 71.06M |
| September 30, 2023 | 57.75M |
| June 30, 2023 | 62.36M |
| March 31, 2023 | 59.89M |
| December 31, 2022 | 63.45M |
| September 30, 2022 | 61.94M |
| June 30, 2022 | 59.03M |
| March 31, 2022 | 55.74M |
| December 31, 2021 | 77.50M |
| September 30, 2021 | 61.74M |
| June 30, 2021 | 62.69M |
| March 31, 2021 | 58.62M |
| December 31, 2020 | 62.51M |
| September 30, 2020 | 52.53M |
| June 30, 2020 | 55.62M |
| March 31, 2020 | 50.67M |
| December 31, 2019 | 54.09M |
| September 30, 2019 | 46.92M |
| June 30, 2019 | 54.35M |
| March 31, 2019 | 32.49M |
| December 31, 2018 | 21.44M |
| September 30, 2018 | 29.93M |
| June 30, 2018 | 44.95M |
| March 31, 2018 | 39.19M |
| Date | Value |
|---|---|
| December 31, 2017 | 18.92M |
| September 30, 2017 | 32.56M |
| June 30, 2017 | 38.61M |
| March 31, 2017 | 34.23M |
| December 31, 2016 | 42.00M |
| September 30, 2016 | 43.73M |
| June 30, 2016 | 38.39M |
| March 31, 2016 | 37.98M |
| December 31, 2015 | 42.60M |
| September 30, 2015 | 34.51M |
| June 30, 2015 | 33.97M |
| March 31, 2015 | 32.23M |
| December 31, 2014 | 35.89M |
| September 30, 2014 | 31.58M |
| June 30, 2014 | 30.86M |
| March 31, 2014 | 29.91M |
| December 31, 2013 | 28.68M |
| September 30, 2013 | 32.62M |
| June 30, 2013 | 31.04M |
| March 31, 2013 | 31.31M |
| December 31, 2012 | 25.31M |
| September 30, 2012 | 27.13M |
| June 30, 2012 | 27.32M |
| March 31, 2012 | 28.03M |
| December 31, 2011 | 35.31M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
46.92M
Minimum
Sep 2019
77.50M
Maximum
Dec 2021
59.02M
Average
58.82M
Median
Research and Development Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 8.519M |
| TC BioPharm (Holdings) PLC | -- |
| DaVita Inc | -- |
| Bicycle Therapeutics PLC | 34.86M |